NCT03386942: A Study of MORAb-202 in Participants With Solid Tumors

NCT03386942
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: FRA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older åÊ (Adult, Senior)
Location of Metastases: 
Additional Notes: Must be folate receptor alpha (FRA)+
Exclusions: Participants with brain or subdural metastases are not eligible, unless they have completed local therapy- see trial for details
https://ClinicalTrials.gov/show/NCT03386942

Comments are closed.

Up ↑